O	O	0	10	Activation	Activation	B-NP	NN	O	7	NMOD	O
O	O	11	13	of	of	B-PP	IN	O	1	NMOD	O
O	O	14	21	protein	protein	B-NP	NN	B-protein	5	NMOD	B-protein
O	O	22	28	kinase	kinase	I-NP	NN	I-protein	5	NMOD	I-protein
O	O	29	30	C	C	I-NP	NN	I-protein	2	PMOD	I-protein
O	O	31	34	and	and	O	CC	O	7	NMOD	O
O	O	35	44	elevation	elevation	B-NP	NN	O	10	SUB	O
O	O	45	47	of	of	B-PP	IN	O	7	NMOD	O
T11	B-Entity	48	52	cAMP	cAMP	B-NP	NN	O	8	PMOD	O
O	O	53	61	interact	interact	B-VP	VBP	O	0	ROOT	O
O	O	62	77	synergistically	synergistically	B-ADVP	RB	O	10	VMOD	O
O	O	78	80	to	to	B-VP	TO	O	13	VMOD	O
O	O	81	86	raise	raise	I-VP	VB	O	10	VMOD	O
T1	B-Protein	87	88	c	c	B-NP	NN	B-protein	21	NMOD	B-protein
T1	I-Protein	88	89	-	-	I-NP	HYPH	I-protein	21	NMOD	I-protein
T1	I-Protein	89	92	Fos	Fos	I-NP	NN	I-protein	21	NMOD	I-protein
O	O	93	96	and	and	I-NP	CC	O	21	NMOD	O
O	O	97	99	AP	AP	I-NP	NN	B-protein	21	NMOD	B-protein
O	O	99	100	-	-	B-NP	HYPH	I-protein	21	NMOD	I-protein
O	O	100	101	1	1	I-NP	CD	I-protein	21	NMOD	I-protein
O	O	102	110	activity	activity	I-NP	NN	O	13	OBJ	O
O	O	111	113	in	in	B-PP	IN	O	21	NMOD	O
O	O	114	120	Jurkat	Jurkat	B-NP	NN	B-cell_line	24	NMOD	B-cell_line
O	O	121	126	cells	cell	I-NP	NNS	I-cell_line	22	PMOD	I-cell_line
O	O	126	127	.	.	O	.	O	10	P	O

O	O	129	131	We	We	B-NP	PRP	O	2	SUB	O
O	O	132	136	have	have	B-VP	VBP	O	0	ROOT	O
O	O	137	144	earlier	earlier	I-VP	RBR	O	2	VMOD	O
O	O	145	150	found	find	I-VP	VBN	O	2	VC	O
O	O	151	155	that	that	B-SBAR	IN	O	4	VMOD	O
O	O	156	158	in	in	B-PP	IN	O	17	VMOD	O
O	O	159	165	Jurkat	Jurkat	B-NP	NN	B-cell_line	8	NMOD	B-cell_line
O	O	166	171	cells	cell	I-NP	NNS	I-cell_line	6	PMOD	I-cell_line
O	O	172	182	activation	activation	B-NP	NN	O	17	SUB	O
O	O	183	185	of	of	B-PP	IN	O	9	NMOD	O
O	O	186	193	protein	protein	B-NP	NN	B-protein	13	NMOD	B-protein
O	O	194	200	kinase	kinase	I-NP	NN	I-protein	13	NMOD	I-protein
O	O	201	202	C	C	I-NP	NN	I-protein	10	PMOD	I-protein
O	O	203	204	(	(	O	(	O	16	DEP	O
O	O	204	207	PKC	PKC	B-NP	NN	B-protein	16	DEP	B-protein
O	O	207	208	)	)	O	)	O	13	NMOD	O
O	O	209	217	enhances	enhance	B-VP	VBZ	O	5	SBAR	O
O	O	218	221	the	the	B-NP	DT	O	25	NMOD	O
T12	B-Entity	222	228	cyclic	cyclic	I-NP	JJ	O	21	NMOD	O
T12	I-Entity	229	238	adenosine	adenosine	I-NP	NN	O	21	NMOD	O
T12	I-Entity	239	252	monophosphate	monophosphate	I-NP	NN	O	25	NMOD	O
O	O	253	254	(	(	O	(	O	24	DEP	O
T13	B-Entity	254	258	cAMP	cAMP	B-NP	NN	O	24	DEP	O
O	O	258	259	)	)	O	)	O	21	NMOD	O
O	O	260	272	accumulation	accumulation	B-NP	NN	O	17	OBJ	O
O	O	273	280	induced	induce	B-VP	VBN	O	25	NMOD	O
O	O	281	283	by	by	B-PP	IN	O	26	VMOD	O
O	O	284	293	adenosine	adenosine	B-NP	NN	B-protein	30	NMOD	B-protein
O	O	294	302	receptor	receptor	I-NP	NN	I-protein	30	NMOD	I-protein
O	O	303	314	stimulation	stimulation	I-NP	NN	O	32	NMOD	O
O	O	315	317	or	or	O	CC	O	32	NMOD	O
O	O	318	328	activation	activation	B-NP	NN	O	27	PMOD	O
O	O	329	331	of	of	B-PP	IN	O	32	NMOD	O
O	O	332	334	Gs	Gs	B-NP	NN	B-protein	33	PMOD	B-protein
O	O	334	335	.	.	O	.	O	2	P	O

O	O	336	340	Here	Here	B-ADVP	RB	O	3	VMOD	O
O	O	341	343	we	we	B-NP	PRP	O	3	SUB	O
O	O	344	348	have	have	B-VP	VBP	O	0	ROOT	O
O	O	349	358	therefore	therefore	I-VP	RB	O	3	VMOD	O
O	O	359	367	examined	examine	I-VP	VBN	O	3	VC	O
O	O	368	371	the	the	B-NP	DT	O	7	NMOD	O
O	O	372	378	effect	effect	I-NP	NN	O	5	OBJ	O
O	O	379	381	of	of	B-PP	IN	O	7	NMOD	O
O	O	382	385	the	the	B-NP	DT	O	12	NMOD	O
O	O	386	393	phorbol	phorbol	I-NP	NN	O	12	NMOD	O
O	O	394	399	ester	ester	I-NP	NN	O	12	NMOD	O
O	O	400	403	PMA	PMA	I-NP	NN	O	8	PMOD	O
O	O	404	405	(	(	O	(	O	21	DEP	O
O	O	405	412	phorbol	phorbol	B-NP	NN	O	21	DEP	O
O	O	413	415	12	12	I-NP	CD	O	14	NMOD	O
O	O	415	416	-	-	O	HYPH	O	21	P	O
O	O	416	425	myristate	myristate	B-NP	NN	B-protein	20	NMOD	B-protein
O	O	426	428	13	13	I-NP	CD	I-protein	17	NMOD	I-protein
O	O	428	429	-	-	I-NP	HYPH	O	17	P	O
O	O	429	436	acetate	acetate	I-NP	NN	O	21	DEP	O
O	O	436	437	)	)	O	)	O	12	NMOD	O
O	O	438	443	which	which	B-NP	WDT	O	12	NMOD	O
O	O	444	454	stimulates	stimulate	B-VP	VBZ	O	22	SBAR	O
T2	B-Protein	455	458	PKC	PKC	B-NP	NN	B-protein	27	NMOD	B-protein
O	O	459	462	and	and	O	CC	O	27	NMOD	O
O	O	463	464	a	a	B-NP	DT	O	27	NMOD	O
O	O	465	476	combination	combination	I-NP	NN	O	50	SUB	O
O	O	477	479	of	of	B-PP	IN	O	27	NMOD	O
O	O	480	483	the	the	B-NP	DT	O	32	NMOD	O
T14	B-Entity	484	493	adenosine	adenosine	I-NP	NN	B-protein	32	NMOD	B-protein
T14	I-Entity	494	502	receptor	receptor	I-NP	NN	I-protein	32	NMOD	I-protein
T14	I-Entity	503	510	agonist	agonist	I-NP	NN	O	33	NMOD	O
T15	I-Entity	511	515	NECA	NECA	I-NP	NN	O	48	NMOD	O
O	O	516	517	(	(	O	(	O	46	DEP	O
T16	B-Entity	517	518	5	5	B-NP	CD	O	45	NMOD	O
T16	I-Entity	518	519	'	'	O	SYM	O	37	AMOD	O
T16	I-Entity	519	520	-	-	O	HYPH	O	35	P	O
T16	I-Entity	520	521	(	(	O	(	O	42	DEP	O
T16	I-Entity	521	522	N	N	B-NP	NN	O	41	NMOD	O
T16	I-Entity	522	523	-	-	B-NP	HYPH	O	41	P	O
T16	I-Entity	523	528	ethyl	ethyl	I-NP	NN	O	42	DEP	O
T16	I-Entity	528	529	)	)	O	)	O	35	NMOD	O
T16	I-Entity	529	530	-	-	B-NP	HYPH	O	45	NMOD	O
T16	I-Entity	530	541	carboxamido	carboxamido	I-NP	NN	O	45	NMOD	O
T16	I-Entity	542	551	adenosine	adenosine	I-NP	NN	O	46	DEP	O
O	O	551	552	)	)	O	)	O	33	NMOD	O
O	O	553	556	and	and	O	CC	O	48	NMOD	O
O	O	557	566	forskolin	forskolin	B-NP	NN	O	28	PMOD	O
O	O	567	569	to	to	B-VP	TO	O	50	VMOD	O
O	O	570	575	raise	raise	I-VP	VB	O	23	VMOD	O
T17	B-Entity	576	580	cAMP	cAMP	B-NP	NN	O	50	OBJ	O
O	O	580	581	,	,	O	,	O	5	P	O
O	O	582	584	on	on	B-PP	IN	O	5	VMOD	O
O	O	585	588	the	the	B-NP	DT	O	55	NMOD	O
O	O	589	595	levels	level	I-NP	NNS	O	53	PMOD	O
O	O	596	598	of	of	B-PP	IN	O	55	NMOD	O
T3	B-Protein	599	600	c	c	B-NP	NN	B-protein	61	NMOD	B-protein
T3	I-Protein	600	601	-	-	B-NP	HYPH	I-protein	61	NMOD	I-protein
T3	I-Protein	601	604	Fos	Fos	I-NP	NN	I-protein	61	NMOD	I-protein
O	O	605	608	and	and	I-NP	CC	O	61	NMOD	O
T4	B-Protein	609	612	Jun	Jun	I-NP	NN	B-protein	56	PMOD	B-protein
O	O	613	616	and	and	B-PP	CC	O	53	PMOD	O
O	O	617	619	on	on	B-PP	IN	O	53	PMOD	O
O	O	620	623	the	the	B-NP	DT	O	68	NMOD	O
O	O	624	631	binding	binding	I-NP	NN	O	68	NMOD	O
O	O	632	635	and	and	O	CC	O	68	NMOD	O
O	O	636	651	transcriptional	transcriptional	B-NP	JJ	O	68	NMOD	O
O	O	652	660	activity	activity	I-NP	NN	O	63	PMOD	O
O	O	661	663	of	of	B-PP	IN	O	68	NMOD	O
O	O	664	667	the	the	B-NP	DT	O	72	NMOD	O
O	O	668	681	transcription	transcription	I-NP	NN	B-protein	72	NMOD	B-protein
O	O	682	688	factor	factor	I-NP	NN	I-protein	75	NMOD	I-protein
O	O	688	689	,	,	O	,	O	75	P	O
T18	B-Entity	690	699	activator	activator	B-NP	NN	B-protein	75	NMOD	B-protein
T18	I-Entity	700	707	protein	protein	I-NP	NN	I-protein	69	PMOD	I-protein
T18	I-Entity	707	708	-	-	B-NP	HYPH	O	77	P	O
T18	I-Entity	708	709	1	1	I-NP	CD	O	75	NMOD	O
O	O	710	711	(	(	O	(	O	82	DEP	O
T19	B-Entity	711	713	AP	AP	B-NP	NN	B-protein	80	NMOD	B-protein
T19	I-Entity	713	714	-	-	B-NP	HYPH	I-protein	82	DEP	I-protein
T19	I-Entity	714	715	1	1	I-NP	CD	I-protein	80	NMOD	I-protein
O	O	715	716	)	)	O	)	O	75	NMOD	O
O	O	716	717	.	.	O	.	O	3	P	O

O	O	718	721	PMA	PMA	B-NP	NN	O	2	NMOD	O
O	O	722	731	treatment	treatment	I-NP	NN	O	3	SUB	O
O	O	732	738	caused	cause	B-VP	VBD	O	0	ROOT	O
O	O	739	740	a	a	B-NP	DT	O	5	NMOD	O
O	O	741	754	concentration	concentration	I-NP	NN	O	11	NMOD	O
O	O	754	755	-	-	O	HYPH	O	5	P	O
O	O	756	759	and	and	O	CC	O	11	NMOD	O
O	O	760	764	time	time	B-NP	NN	O	11	NMOD	O
O	O	764	765	-	-	B-NP	HYPH	O	11	NMOD	O
O	O	765	774	dependent	dependent	I-NP	JJ	O	11	NMOD	O
O	O	775	783	increase	increase	I-NP	NN	O	3	OBJ	O
O	O	784	786	in	in	B-PP	IN	O	11	NMOD	O
O	O	787	791	both	both	O	CC	O	18	NMOD	O
T5	B-Protein	792	793	c	c	B-NP	NN	O	18	NMOD	O
T5	I-Protein	793	794	-	-	I-NP	HYPH	O	18	P	O
T5	I-Protein	794	797	Fos	Fos	I-NP	NN	B-protein	18	NMOD	B-protein
O	O	798	801	and	and	I-NP	CC	O	18	NMOD	O
T6	B-Protein	802	805	Jun	Jun	I-NP	NN	B-protein	19	NMOD	B-protein
O	O	806	822	immunoreactivity	immunoreactivity	I-NP	NN	O	12	PMOD	O
O	O	823	825	in	in	B-PP	IN	O	3	VMOD	O
O	O	826	834	contrast	contrast	B-NP	NN	O	20	PMOD	O
O	O	835	837	to	to	B-PP	TO	O	21	NMOD	O
T20	B-Entity	838	842	cAMP	cAMP	B-NP	NN	O	24	NMOD	O
O	O	843	852	elevation	elevation	I-NP	NN	O	22	PMOD	O
O	O	853	857	that	that	B-NP	WDT	O	24	NMOD	O
O	O	858	861	had	have	B-VP	VBD	O	25	SBAR	O
O	O	862	866	only	only	B-NP	RB	O	30	NMOD	O
O	O	867	868	a	a	I-NP	DT	O	30	NMOD	O
O	O	869	875	slight	slight	I-NP	JJ	O	30	NMOD	O
O	O	876	882	effect	effect	I-NP	NN	O	26	OBJ	O
O	O	882	883	.	.	O	.	O	3	P	O

O	O	884	888	Both	Both	O	CC	O	5	NMOD	O
O	O	889	892	PMA	PMA	B-NP	NN	O	5	NMOD	O
O	O	893	896	and	and	O	CC	O	5	NMOD	O
O	O	897	900	the	the	B-NP	DT	O	5	NMOD	O
O	O	901	912	combination	combination	I-NP	NN	O	10	SUB	O
O	O	913	915	of	of	B-PP	IN	O	5	NMOD	O
T21	B-Entity	916	920	NECA	NECA	B-NP	NN	B-protein	9	NMOD	B-protein
O	O	921	924	and	and	I-NP	CC	O	9	NMOD	O
O	O	925	934	forskolin	forskolin	I-NP	NN	O	6	PMOD	O
O	O	935	940	acted	act	B-VP	VBD	O	0	ROOT	O
O	O	941	949	together	together	B-ADVP	RB	O	10	VMOD	O
O	O	950	956	either	either	O	CC	O	14	VMOD	O
O	O	957	959	to	to	B-VP	TO	O	14	VMOD	O
O	O	960	968	increase	increase	I-VP	VB	O	10	VMOD	O
O	O	969	970	(	(	O	(	O	19	DEP	O
T7	B-Protein	970	971	c	c	O	NN	B-protein	18	NMOD	B-protein
T7	I-Protein	971	972	-	-	O	HYPH	I-protein	18	P	I-protein
T7	I-Protein	972	975	Fos	Fos	B-NP	NN	I-protein	19	DEP	I-protein
O	O	975	976	)	)	O	)	O	14	VMOD	O
O	O	977	979	or	or	O	CC	O	14	VMOD	O
O	O	980	988	decrease	decrease	B-NP	NN	O	26	NMOD	O
O	O	989	990	(	(	O	(	O	24	DEP	O
T8	B-Protein	990	993	Jun	Jun	B-NP	NN	B-protein	24	DEP	B-protein
O	O	993	994	)	)	O	)	O	21	NMOD	O
O	O	995	1002	protein	protein	B-NP	NN	O	26	NMOD	O
O	O	1003	1009	levels	level	I-NP	NNS	O	49	NMOD	O
O	O	1010	1012	as	as	B-CONJP	RB	O	49	NMOD	O
O	O	1013	1017	well	well	I-CONJP	RB	O	27	DEP	O
O	O	1018	1020	as	as	I-CONJP	IN	O	27	DEP	O
O	O	1021	1031	increasing	increase	B-VP	VBG	O	49	NMOD	O
T22	B-Entity	1032	1034	AP	AP	B-NP	NN	B-protein	34	NMOD	B-protein
T22	I-Entity	1034	1035	-	-	I-NP	HYPH	I-protein	34	NMOD	I-protein
T22	I-Entity	1035	1036	1	1	I-NP	CD	I-protein	34	NMOD	I-protein
O	O	1037	1044	binding	binding	I-NP	NN	O	30	OBJ	O
O	O	1044	1045	,	,	O	,	O	30	P	O
O	O	1046	1048	as	as	B-SBAR	IN	O	30	VMOD	O
O	O	1049	1055	judged	judge	B-VP	VBN	O	36	SBAR	O
O	O	1056	1058	by	by	B-PP	IN	O	37	VMOD	O
O	O	1059	1062	gel	gel	B-NP	NN	O	42	NMOD	O
O	O	1062	1063	-	-	I-NP	HYPH	O	42	NMOD	O
O	O	1063	1068	shift	shift	I-NP	NN	O	42	NMOD	O
O	O	1069	1074	assay	assay	I-NP	NN	O	38	PMOD	O
O	O	1074	1075	,	,	O	,	O	49	P	O
O	O	1076	1079	and	and	O	CC	O	49	NMOD	O
T23	B-Entity	1080	1082	AP	AP	B-NP	NN	B-protein	46	NMOD	B-protein
T23	I-Entity	1082	1083	-	-	B-NP	HYPH	I-protein	49	NMOD	I-protein
T23	I-Entity	1083	1084	1	1	I-NP	CD	I-protein	46	NMOD	I-protein
O	O	1085	1100	transcriptional	transcriptional	I-NP	JJ	O	49	NMOD	O
O	O	1101	1109	activity	activity	I-NP	NN	O	14	VMOD	O
O	O	1109	1110	.	.	O	.	O	10	P	O

O	O	1111	1122	Furthermore	Furthermore	B-ADVP	RB	O	3	VMOD	O
O	O	1123	1128	there	there	B-NP	EX	O	3	SUB	O
O	O	1129	1132	was	be	B-VP	VBD	O	0	ROOT	O
O	O	1133	1134	a	a	B-NP	DT	O	8	NMOD	O
O	O	1135	1140	clear	clear	I-NP	JJ	O	8	NMOD	O
O	O	1140	1141	-	-	I-NP	HYPH	O	8	NMOD	O
O	O	1141	1144	cut	cut	I-NP	NN	O	8	NMOD	O
O	O	1145	1152	synergy	synergy	I-NP	NN	O	3	PRD	O
O	O	1153	1160	between	between	B-PP	IN	O	8	NMOD	O
O	O	1161	1164	the	the	B-NP	DT	O	12	NMOD	O
T9	B-Protein	1165	1168	PKC	PKC	I-NP	NN	B-protein	12	NMOD	B-protein
O	O	1169	1179	stimulator	stimulator	I-NP	NN	O	17	NMOD	O
O	O	1180	1183	and	and	O	CC	O	17	NMOD	O
O	O	1184	1187	the	the	B-NP	DT	O	17	NMOD	O
T24	B-Entity	1188	1192	cAMP	cAMP	I-NP	NN	O	17	NMOD	O
O	O	1193	1202	elevating	elevate	B-VP	VBG	O	17	NMOD	O
O	O	1203	1209	agents	agent	B-NP	NNS	O	9	PMOD	O
O	O	1209	1210	.	.	O	.	O	3	P	O

O	O	1211	1214	The	The	B-NP	DT	O	2	NMOD	O
O	O	1215	1222	results	result	I-NP	NNS	O	3	SUB	O
O	O	1223	1234	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT	O
O	O	1235	1239	that	that	B-SBAR	IN	O	3	VMOD	O
O	O	1240	1243	the	the	B-NP	DT	O	7	NMOD	O
O	O	1244	1256	simultaneous	simultaneous	I-NP	JJ	O	7	NMOD	O
O	O	1257	1267	activation	activation	I-NP	NN	O	11	NMOD	O
O	O	1268	1270	of	of	B-PP	IN	O	7	NMOD	O
T10	B-Protein	1271	1274	PKC	PKC	B-NP	NN	B-protein	8	PMOD	B-protein
O	O	1275	1278	and	and	I-NP	CC	O	11	NMOD	O
O	O	1279	1288	elevation	elevation	I-NP	NN	O	14	SUB	O
O	O	1289	1291	of	of	B-PP	IN	O	11	NMOD	O
T25	B-Entity	1292	1296	cAMP	cAMP	B-NP	NN	O	12	PMOD	O
O	O	1297	1302	leads	lead	B-VP	VBZ	O	4	SBAR	O
O	O	1303	1305	to	to	B-PP	TO	O	14	VMOD	O
O	O	1306	1308	an	an	B-NP	DT	O	22	NMOD	O
O	O	1309	1317	enhanced	enhance	I-NP	VBN	O	22	NMOD	O
T26	B-Entity	1318	1320	AP	AP	I-NP	NN	B-protein	22	NMOD	B-protein
T26	I-Entity	1320	1321	-	-	B-NP	HYPH	I-protein	22	NMOD	I-protein
T26	I-Entity	1321	1322	1	1	I-NP	CD	I-protein	22	NMOD	I-protein
O	O	1323	1338	transcriptional	transcriptional	I-NP	JJ	O	22	NMOD	O
O	O	1339	1347	activity	activity	I-NP	NN	O	15	PMOD	O
O	O	1348	1350	in	in	B-PP	IN	O	22	NMOD	O
O	O	1351	1352	a	a	B-NP	DT	O	29	NMOD	O
O	O	1353	1354	T	T	I-NP	NN	B-cell_line	29	NMOD	B-cell_line
O	O	1354	1355	-	-	I-NP	HYPH	I-cell_line	29	NMOD	I-cell_line
O	O	1355	1363	leukemia	leukemia	I-NP	NN	I-cell_line	29	NMOD	I-cell_line
O	O	1364	1368	cell	cell	I-NP	NN	I-cell_line	29	NMOD	I-cell_line
O	O	1369	1373	line	line	I-NP	NN	I-cell_line	23	PMOD	I-cell_line
O	O	1373	1374	,	,	O	,	O	14	P	O
O	O	1375	1385	suggesting	suggest	B-VP	VBG	O	14	VMOD	O
O	O	1386	1390	that	that	B-SBAR	IN	O	31	VMOD	O
O	O	1391	1394	the	the	B-NP	DT	O	36	NMOD	O
O	O	1395	1405	previously	previously	I-NP	RB	O	35	AMOD	O
O	O	1406	1414	observed	observe	I-NP	VBN	O	36	NMOD	O
O	O	1415	1426	interaction	interaction	I-NP	NN	O	43	SUB	O
O	O	1427	1434	between	between	B-PP	IN	O	36	NMOD	O
O	O	1435	1438	the	the	B-NP	DT	O	42	NMOD	O
O	O	1439	1447	parallel	parallel	I-NP	JJ	O	42	NMOD	O
O	O	1448	1454	signal	signal	I-NP	NN	O	42	NMOD	O
O	O	1455	1467	transduction	transduction	I-NP	NN	O	42	NMOD	O
O	O	1468	1476	pathways	pathway	I-NP	NNS	O	37	PMOD	O
O	O	1477	1480	may	may	B-VP	MD	O	32	SBAR	O
O	O	1481	1485	have	have	I-VP	VB	O	43	VC	O
O	O	1486	1496	functional	functional	B-NP	JJ	O	46	NMOD	O
O	O	1497	1509	consequences	consequence	I-NP	NNS	O	44	OBJ	O
O	O	1510	1512	at	at	B-PP	IN	O	44	VMOD	O
O	O	1513	1516	the	the	B-NP	DT	O	49	NMOD	O
O	O	1517	1522	level	level	I-NP	NN	O	47	PMOD	O
O	O	1523	1525	of	of	B-PP	IN	O	49	NMOD	O
O	O	1526	1530	gene	gene	B-NP	NN	O	52	NMOD	O
O	O	1531	1544	transcription	transcription	I-NP	NN	O	50	PMOD	O
O	O	1544	1545	.	.	O	.	O	3	P	O
